CoChat

Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment

Open access
Jensen, Lene, Kupcova, Viera, Arold, Gerhard, Pettersson, Jonas, Hjerpsted, Julie B. · 2018 · Diabetes, Obesity and Metabolism
Cited by 76

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Aims: To investigate whether the pharmacokinetic characteristics of semaglutide were altered in people with hepatic impairment, assessed using Child–Pugh criteria, vs those with normal hepatic function. Methods: In this multicentre, open‐label, parallel‐group trial (sponsor Novo Nordisk, ClinicalTrials.gov ID NCT02210871), four groups of participants with normal hepatic function ( n = 19) or mild ( n = 8), moderate ( n = 10) or severe ( n = 7) hepatic impairment received a single, subcutaneous dose of 0.5 mg semaglutide. Semaglutide plasma concentrations were assessed frequently for 35 days after dosing. The primary endpoint was area under the semaglutide plasma concentration–time curve from time zero to infinity (AUC 0‐∞ ). No effect of hepatic impairment was declared if the 90% confidence interval (CI) for the between‐group ratio (hepatic impairment/normal function) was within the interval 0.70 to 1.43. Results: Semaglutide exposure was similar across all groups, with AUC 0‐∞ treatment ratios for mild impairment/normal function of 0.95 (90% CI 0.77, 1.16), moderate impairment/normal function 1.02 (90% CI 0.93, 1.12), and severe impairment/normal function 0.97 (90% CI 0.84, 1.12). The maximum plasma semaglutide concentration (C max ) did not appear to be influenced by hepatic function, with mild impairment/normal function treatment ratios of 0.99 (90% CI 0.80, 1.23), moderate impairment/normal function 1.02 (90% CI 0.88, 1.18) and severe impairment/normal function 1.15 (90% CI 0.89, 1.48; sensitivity analysis excluding one extreme semaglutide concentration: 1.05 [90% CI 0.88, 1.25]). In all, 10 participants reported 12 mild or moderate non‐serious adverse events. No unexpected safety or tolerability issues were observed. Conclusions: Semaglutide exposure did not appear to be affected by hepatic impairment, suggesting that dose adjustment may not be necessary in patients with hepatic impairment. Semaglutide was well tolerated and there were no unexpected safety issues.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13186

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 76

Metadata

Authors
Jensen, L., Kupcova, V., Arold, G., Pettersson, J., & Hjerpsted, J. B.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2018-01-17
Volume
20
Issue
4
Pages
998-1005
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2773698516
Cited by
76
References
12
FWCI
4.64
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment. https://app.cochat.ai/papers/10.1111/dom.13186
The paper
Jensen, L., Kupcova, V., Arold, G., Pettersson, J., & Hjerpsted, J. B. (2018). Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13186

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.